

## **AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 8, 2018**

April 30, 2018

GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended March 31, 2018 after the market closes on Tuesday, May 8<sup>th</sup>, 2018. AGTC management will host a conference call beginning at 4:30 pm Eastern Time that day to review results and provide a corporate update.

To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The passcode is 13678555. A live webcast will be available in the Events and Presentations section of the Investor Relations page at <http://ir.agtc.com/events-and-presentations>. Please log in approximately 10 minutes prior to the scheduled start time.

The archived webcast will be available in the Events and Presentations section of the company's website.

### **About AGTC**

AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinoschisis (XLRs), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 & ACHM CNGB3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and otology. The clinical-stage XLRs and XLRP programs, the discovery program in ALD and two additional ophthalmology programs are being developed in collaboration with Biogen. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.

### **AGTC IR/PR CONTACTS:**

David Carey (IR) or Tom Vickery (PR)  
Lazar Partners Ltd.  
T: (212) 867-1768 or (646) 871-8482  
[dcarey@lazarpartners.com](mailto:dcarey@lazarpartners.com) or [tvickery@lazarpartners.com](mailto:tvickery@lazarpartners.com)

### **CORPORATE CONTACTS:**

Bill Sullivan  
Chief Financial Officer  
Applied Genetic Technologies Corporation  
T: (617) 843-5728  
[bsullivan@agtc.com](mailto:bsullivan@agtc.com)

Stephen Potter  
Chief Business Officer  
Applied Genetic Technologies Corporation  
T: (617) 413-2754  
[spotter@agtc.com](mailto:spotter@agtc.com)

[Primary Logo](#)

Source: Applied Genetic Technologies Corporation